摘要
目的分析奥拉帕尼抑制卵巢癌SKOV3细胞增殖的PI3K/AKT/mTOR信号通路机制。方法将生长状态良好的SK-OV3细胞随机分为5组:对照组、奥拉帕尼低剂量组(10 mg·L^(-1))、奥拉帕尼中剂量组(30 mg·L^(-1))、奥拉帕尼高剂量组(90mg·L^(-1))和PI3K蛋白抑制剂LY294002组(10 mg·L^(-1))。除对照组外,其余各组细胞给予相应剂量的化合物孵育,DAPI及免疫印迹法分析细胞凋亡蛋白的表达,q PCR、免疫印迹法和免疫细胞化学法测定PI3K/AKT/mTOR信号通路相关蛋白的表达。结果奥拉帕尼处理后卵巢癌SKOV3细胞增殖明显受到抑制(P<0.05),SKOV3细胞内的凋亡小体逐渐增多,促细胞凋亡蛋白caspase 3及caspase 9的表达逐步增强(P<0.05),PI3K、AKT和mTOR表达逐步降低(P<0.05),且随着奥拉帕尼水平的升高,作用越明显(P<0.05)。结论奥拉帕尼对卵巢癌SKOV3细胞具有剂量依赖性抑制作用,且可能是通过抑制PI3K/AKT/mTOR信号通路发挥作用。
OBJECTIVE To analyze the involvement of PI3K/AKT/mTOR signaling pathway on the inhibiting the proliferation of ovarian cancer SK-OV3 cell line by olaparib.METHODS The SKOV3 cells were randomly divided into five groups:control group,olaparib low dose group(10 mg·L^-1),olaparib medium dose group(30 mg·L^-1),olaparib high dose group(90 mg·L^-1),and PI3K protein inhibitor LY294002 group(10 mg·L^-1).In addition to the control group,the rest of the cells were incubated with the corresponding doses of the compounds.DAPI and Western blotting were used to analyze the expression of apoptotic protein.qPCR,Western blotting and immunocytochemistry were adopted to detect the expression of PI3K/AKT/mTOR signaling pathway related proteins.RESULTS After olaparib treatment,the proliferation of ovarian cancer SKOV3 cells was significantly inhibited(P<0.05).Apoptotic bodies in SKOV3 cells increased gradually,and the expression of caspase 3 and caspase 9 increased gradually(P<0.05),PI3K,AKT and mTOR expression gradually decreased(P<0.05)after olaparib medication.With the increase of olaparib level,the above effects were more obvious(P<0.05).CONCLUSION Olaparib has an inhibitory effect on ovarian cancer SKOV3 cells,and it may play a role by inhibiting the PI3K/AKT/mTOR signaling pathway.
作者
马艳英
袁博
赵文伯
赵冬梅
MA Yan-ying;YUAN Bo;ZHAO Wen-bo;ZHAO Dong-mei(Department of Pathology,the Affiliated Cancer Hospital of Zhengzhou University,Zhengzhou 450003,China;Department of Obstetrics and Gynecology,the Second Affiliated Hospital of Zhengzhou University, Zhengzhou 450014,China;College of Chemistry and Chemical Engineering,Zhengzhou Normal University,Zhengzhou 450044,China)
出处
《中国药学杂志》
CAS
CSCD
北大核心
2019年第1期36-41,共6页
Chinese Pharmaceutical Journal
基金
河南省医学科技攻关计划项目资助(201702090)
河南省自然科学基金(152300410001)